Key result
Rabeprazole was preferred over other PPIs by 91.9% of surveyed healthcare professionals for managing GERD in patients on polypharmacy due to its minimal drug-drug interactions.
Why the study?
Managing the safety and efficacy of PPIs in GERD patients on polypharmacy is challenging, prompting an exploration of the safety and effectiveness of rabeprazole in Indian comorbid GERD patients on polypharmacy.
Do healthcare professionals prefer rabeprazole over other PPIs for managing GERD in patients on polypharmacy and antiplatelet therapy?
Cross-Sectional
Do healthcare professionals prefer rabeprazole over other PPIs for managing GERD in patients on polypharmacy and antiplatelet therapy?
A survey of Indian healthcare professionals indicates a strong preference for rabeprazole in GERD patients on polypharmacy, largely due to its minimal CYP450 interactions and perceived safety with antiplatelet therapy.
Survey preference for rabeprazole in polypharmacy GERD is hypothesis-generating; leaves open need for outcome trials with antiplatelet therapy.
BACKGROUND: The safety and efficacy of proton-pump inhibitors (PPIs) in gastroesophageal reflux disease (GERD) patients on polypharmacy is challenging to manage. Rabeprazole's unique metabolism reduces drug-drug interactions (DDI), making it beneficial for patients with polypharmacy. This study aimed to explore the safety and effectiveness of rabeprazole in Indian comorbid GERD patients on polypharmacy. METHODS: A cross-sectional survey was conducted (November, 2024 and January, 2025), which included healthcare professionals (HCPs) with experience in prescribing PPIs. The survey included 10 questions addressing issues faced in polypharmacy settings. RESULTS: Around 91.9% preferred prescribing rabeprazole over other PPIs in polypharmacy patients. CYP450 enzyme interactions are considered by 73.3% HCPs when prescribing PPIs, with a strong emphasis on minimizing DDI in polypharmacy contexts. Rabeprazole was chosen by a major share of HCPs for its unique nonenzymatic metabolism and minimal interaction with the cytochrome P450 system, suggesting suitability in polypharmacy patients. Furthermore, 70% HCPs suggested rabeprazole could improve cardiovascular (CV) outcomes by optimizing antiplatelet therapy, and 74.4% supported its safety in patients on antiplatelet therapy. CONCLUSION: Rabeprazole appears to be the preferred PPI in managing GERD among patients on polypharmacy, primarily due to its favorable safety profile and minimal DDI, and may be advantageous in clinical practice.
No takes yet. Share an insight, caveat, or question.
Juneja et al. (2025) conducted a cross-sectional in Gastroesophageal reflux disease (GERD) with polypharmacy. Rabeprazole vs. Other proton-pump inhibitors was evaluated on HCP preference for prescribing rabeprazole over other PPIs in polypharmacy patients. Rabeprazole was preferred over other PPIs by 91.9% of surveyed healthcare professionals for managing GERD in patients on polypharmacy due to its minimal drug-drug interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: